Skip to content

Adductor Canal Block Methods in Bilateral Total Knee Arthroplasty

Comparison of Surgeon-Performed Intraoperative Adductor Canal Block and Ultrasound-Guided Anesthesiologist-Performed Block in Bilateral Total Knee Arthroplasty

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07506629
Enrollment
48
Registered
2026-04-01
Start date
2026-05-01
Completion date
2029-03-01
Last updated
2026-04-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Total Knee Arthroplasty, Postoperative Pain, Peripheral Nerve Block, Adductor Canal Block

Brief summary

This study aims to compare the analgesic efficacy of surgeon-performed intraoperative adductor canal block (ACB) and ultrasound-guided anesthesiologist-performed ACB in patients undergoing bilateral total knee arthroplasty (TKA). In a prospective, randomized paired design, each patient will receive surgeon-performed ACB on one knee and anesthesiologist-performed ACB on the contralateral knee. The primary outcome is postoperative pain measured using the Numeric Rating Scale (NRS), and the study is designed to evaluate the non-inferiority of surgeon-performed ACB. Secondary outcomes include opioid consumption, time to first ambulation, length of hospital stay, postoperative complications, and patient-reported outcome measures (PROMs). Additionally, postoperative ultrasound evaluation will be performed to assess the distribution pattern of local anesthetic within the adductor canal, including cross-sectional area and longitudinal spread. This study is expected to provide evidence regarding the clinical effectiveness and technical accuracy of surgeon-performed ACB in comparison with the conventional ultrasound-guided technique.

Interventions

BIOLOGICALSurgeon-Performed Adductor Canal Block

An adductor canal block performed intraoperatively by the surgeon using an anatomical landmark-based technique. The injection is administered at approximately 8 cm proximal to the distal femur, with the needle directed medially and posteriorly. A total of 20 mL of 0.3% ropivacaine mixed with epinephrine is injected using a standardized approach without ultrasound guidance.

An adductor canal block performed by an anesthesiologist under ultrasound guidance. The saphenous nerve and femoral artery within the adductor canal are identified using real-time imaging, and 20 mL of 0.3% ropivacaine mixed with epinephrine is injected using an in-plane technique.

Sponsors

Yonsei University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Adult patients aged 19 years or older * Patients scheduled for bilateral total knee arthroplasty * Patients who provide written informed consent

Exclusion criteria

* Refusal to participate or inability to provide informed consent * Neurological or psychiatric conditions affecting cooperation (e.g., dementia, delirium) * Pre-existing neurological or anatomical abnormalities of the lower extremities * Chronic opioid use or opioid dependence * Coagulation disorders or contraindications to nerve block * Pregnancy * Cases in which ultrasound evaluation is technically not feasible

Design outcomes

Primary

MeasureTime frameDescription
Pain (Numeric Rating Scale)Baseline, postoperative day 0 (afternoon), postoperative day 1 (morning and afternoon), and postoperative day 2 (morning)Postoperative pain will be assessed using the Numeric Rating Scale (NRS, 0-10). Pain scores will be recorded at predefined time points under resting conditions. The primary analysis will evaluate the non-inferiority of surgeon-performed adductor canal block compared to ultrasound-guided adductor canal block.

Contacts

CONTACTKwan-Kyu Park, Professor
kkpark@yuhs.ac+82-2-2228-2183

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 2, 2026